Last reviewed · How we verify

TETANUS TOXOID

FDA-approved approved Vaccine component ✓ Verified May 2026 Quality 5/100

TETANUS TOXOID is a drug. It is currently FDA-approved (first approved 1996).

Tetanus toxoid is a vaccine component used in various vaccine formulations, classified as a vaccine antigen. It is used as a vaccine antigen to stimulate an immune response, with its mechanism of action being to provide immunity against tetanus.

At a glance

Generic nameTETANUS TOXOID
ModalityVaccine component
PhaseFDA-approved
First approval1996

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TETANUS TOXOID

What is TETANUS TOXOID?

TETANUS TOXOID is a Vaccine component drug.

When was TETANUS TOXOID approved?

TETANUS TOXOID was first approved on 1996.

What development phase is TETANUS TOXOID in?

TETANUS TOXOID is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing